Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Ken Shirabe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7173-7945; OpenAlex author ID A5012550681. Sources: OpenAlex.

Their work

Papers
23 (first author 0, last author 16)
Trials
0
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 4 papers · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 6 papers

Papers 23

  1. Impact of Histopathological Response on Outcomes After Surgical Resection Following Carbon-Ion Radiotherapy for Pancreatic Cancer With Arterial Involvement. Last author DOI 10.1002/ags3.70259↗
  2. Achievement of the Ideal Outcome After Pancreatectomy for Pancreatic Ductal Adenocarcinoma Is Associated With Earlier Initiation and Higher Completion Rates of… Last author DOI 10.1002/ags3.70270↗
  3. CD86-Positive Mature Tertiary Lymphoid Structures Are Associated With CD8+ T-Cell Infiltration and Favorable Clinical Outcomes in Pancreatic Ductal Adenocarcin… Last author DOI 10.1002/ags3.70275↗
  4. Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database. Co-author DOI 10.1007/s00535-026-02480-8↗
  5. Long-term outcomes of plastic versus metal stents for preoperative biliary drainage in pancreatic cancer: a nationwide propensity score-matched analysis. Co-author DOI 10.1016/j.gie.2026.05.032↗
  6. Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. Co-author DOI 10.1097/mpa.0000000000002694↗
  7. Impact of Preoperative Weight Loss on Prognosis in Patients with Pancreatic Cancer. Last author DOI 10.3390/biomedicines13071703↗
  8. Pancreatic cancer and sarcopenia: a narrative review of the current status. Last author DOI 10.1007/s10147-024-02576-2↗
  9. Potential of Mac-2-binding protein glycan isomer as a new therapeutic target in pancreatic cancer. Last author DOI 10.1111/cas.16087↗
  10. Usefulness of serum creatinine and cystatin C ratio as a screening tool for predicting prognosis in patients with pancreatic cancer. Last author DOI 10.1002/ags3.12671↗
  11. High RRN3 expression is associated with malignant characteristics and poor prognosis in pancreatic cancer. Last author DOI 10.1007/s10147-023-02342-w↗
  12. Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World St… Co-author DOI 10.1159/000525742↗
  13. D-Dimer Could Be a Surrogate Postoperative Prognostic Marker of Resectable Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001537↗
  14. Long-term survival of two patients with pancreatic cancer after resection of liver and lung oligometastases: a case report. Last author DOI 10.1186/s40792-020-01029-y↗
  15. High Co-expression of Large Tenascin C Splice Variants in Stromal Tissue and Annexin A2 in Cancer Cell Membranes is Associated with Poor Prognosis in Pancreati… Last author DOI 10.1245/s10434-019-07708-x↗
  16. ASO Author Reflections: Clinical Significance of Large Tenascin C Splice Variants and Annexin A2 for Pancreatic Cancer. Last author DOI 10.1245/s10434-019-08009-z↗
  17. Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. Last author DOI 10.1111/cas.13847↗
  18. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00280-017-3477-4↗
  19. Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer. Co-author DOI 10.18632/oncotarget.25837↗
  20. High STMN1 Expression Is Associated with Tumor Differentiation and Metastasis in Clinical Patients with Pancreatic Cancer. Last author DOI 10.21873/anticanres.12307↗
  21. Association of RAB5 overexpression in pancreatic cancer with cancer progression and poor prognosis via E-cadherin suppression. Co-author DOI 10.18632/oncotarget.14703↗
  22. Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1. Last author DOI 10.18632/oncotarget.22634↗
  23. Recurrence 11 years after complete response to gemcitabine, 5-Fluorouracil, and Cisplatin chemotherapy followed by radiotherapy in a patient with advanced panc… Co-author PMID 25964569↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichiro Araki · 17 shared papers, 2017–2026 · strength 2.71
  2. Mariko Tsukagoshi · 15 shared papers, 2017–2026 · strength 2.49
  3. Kei Hagiwara · 11 shared papers, 2018–2026 · strength 1.66
  4. Takamichi Igarashi · 10 shared papers, 2017–2026 · strength 1.54
  5. Norihiro Ishii · 11 shared papers, 2017–2026 · strength 1.36
  6. Norifumi Harimoto · 10 shared papers, 2015–2024 · strength 1.19
  7. Akira Watanabe · 11 shared papers, 2017–2024 · strength 1.14
  8. Takehiko Yokobori · 9 shared papers, 2017–2026 · strength 1.03
  9. Atsushi Masamune · 5 shared papers, 2019–2026 · strength 0.96
  10. Takahiro Yamanaka · 8 shared papers, 2017–2024 · strength 0.78
  11. Shin Hamada · 3 shared papers, 2026 · strength 0.71
  12. Sohei Satoi · 3 shared papers, 2026 · strength 0.71
  13. Shinichi Egawa · 3 shared papers, 2026 · strength 0.71
  14. Kohei Nakata · 3 shared papers, 2026 · strength 0.71
  15. Masamichi Mizuma · 3 shared papers, 2026 · strength 0.71
  16. Ichiro Yasuda · 3 shared papers, 2026 · strength 0.71
  17. Yoshifumi Takeyama · 3 shared papers, 2026 · strength 0.71
  18. Michiaki Unno · 3 shared papers, 2026 · strength 0.71
  19. Takao Itoi · 3 shared papers, 2026 · strength 0.71
  20. Ryosuke Fukushima · 2 shared papers, 2025–2026 · strength 0.52
  21. Takaomi Seki · 2 shared papers, 2025–2026 · strength 0.51
  22. Yuzo Kodama · 2 shared papers, 2026 · strength 0.48
  23. Manabu Kawai · 2 shared papers, 2026 · strength 0.47
  24. Kazuichi Okazaki · 2 shared papers, 2026 · strength 0.47
  25. Hiroyuki Kuwano · 6 shared papers, 2017–2019 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.